CompletedNCT02713282
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Researchers studied Paliperidone palmitate 3 month formulation (PP3M) to find out how it affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–50Multiple countries
Understand this study
What did researchers investigate?
Researchers studied Paliperidone palmitate 3 month formulation (PP3M) to find out how it affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- Rijeka, Croatia · Zagreb, Croatia and 46 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: April 28, 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 306
- Sponsor
- Janssen-Cilag Ltd.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France, United Kingdom, Croatia, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT02713282
- Official title
Show the full official title
A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
Recruitment & locations
CompletedRijeka, Croatia · Zagreb, Croatia · Esbjerg, Denmark
45 more locations
- Clermont-Ferrand, France
- Montpellier, France
- Paris, France
- Rennes, France
- Toulon, France
- Berlin, Germany
- Hamburg, Germany
- Oranienburg, Germany
- Stralsund, Germany
- Athens, Greece
- Heraklion, Greece
- Nea Kifissia, Greece
- Thessaloniki, Greece
- Beer Yaakov, Israel
- Ramat Gan, Israel
- Ipoh, Malaysia
- Johor Bahru, Malaysia
- Kuala Lumpur, Malaysia
- Assen, Netherlands
- Groningen, Netherlands
- Moscow, Russia
- Saint Petersburg, Russia
- Jeddah, Saudi Arabia
- Gwangju, South Korea
- Gyeonggi-do, South Korea
- Jeonju, South Korea
- Seoul, South Korea
- Bilbao, Spain
- Madrid, Spain
- Oviedo, Spain
- Sabadell, Spain
- Torrevieja, Spain
- Valencia, Spain
- New Taipei City, Taiwan
- Tainan, Taiwan
- Taoyuan, Taiwan
- Ankara, Türkiye
- Bursa, Türkiye
- Istanbul, Türkiye
- Sakarya, Türkiye
- Derby, United Kingdom
- Edinburgh, United Kingdom
- Reading, United Kingdom
- Russia
- Türkiye
Questions about this study
What did researchers investigate?
Researchers studied Paliperidone palmitate 3 month formulation (PP3M) to find out how it affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen-Cilag Ltd.
Did this study involve medication?
Yes. The study involved medication, including Paliperidone palmitate 3 month formulation (PP3M).
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy